Insmed (INSM) Form 144: Proposed Sale of 10,000 Shares ($1.22M)

Form 144 filed for Insmed, Inc. (INSM) reports a proposed sale of 10,000 shares of common stock through Merrill Lynch in Orlando, to be executed on or about 08/12/2025 on NASDAQ with an aggregate market value of $1,215,350.

Accepted by SEC EDGAR 08/12/2025 - 04:37 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Form 144 filed for Insmed, Inc. (INSM) reports a proposed sale of 10,000 shares of common stock through Merrill Lynch in Orlando, to be executed on or about 08/12/2025 on NASDAQ with an aggregate market value of $1,215,350. The filing lists total shares outstanding of 211,374,786, which makes the proposed block a very small fraction of the company's capitalization.

The securities to be sold were acquired via stock option transactions reported on 05/18/2018 (6,702 shares) and 05/16/2019 (6,066 shares). Several identifying fields in the filing appear blank or unspecified, and the form includes the standard representation that the seller does not possess undisclosed material adverse information.

Positive

• None.

Negative

• Seller identity not specified in the visible filing fields, reducing transparency about who is proposing the sale.
• Filer contact/CIK and signature/date fields are not provided in the content supplied, limiting verifiability of the notice.

Insights

Securities Analyst

TL;DR: Proposed sale of 10,000 INSM shares (~0.0047% of outstanding) valued at $1.215M—immaterial to overall capitalization.

The filing shows a small disposition relative to 211,374,786 shares outstanding: 10,000/211,374,786 equals approximately 0.0047% of the float implied by outstanding shares. The broker is listed as Merrill Lynch (Orlando). The reported acquisition lots (6,702 shares from 05/18/2018 and 6,066 shares from 05/16/2019) indicate the seller holds option-derived lots larger than the proposed sale, but the filing does not identify the named seller in the provided fields. From an investor-impact perspective, the size and timing (08/12/2025) make market impact negligible.

Corporate Governance / Compliance Expert

TL;DR: Routine Rule 144 notice filed but several identification fields are missing, which reduces transparency for market participants.

The form contains the required Rule 144 representation about absence of undisclosed material adverse information and documents the broker and sale details. However, key identifying fields (the filer CIK/contact info and the "Name of Person for Whose Account" appear blank in the provided content), and signature/date entries are not shown. That limits the utility of the filing for due diligence and public record verification, though it does not alter the factual details of the proposed transaction as reported.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the INSM Form 144 disclose?

It discloses a proposed sale of 10,000 common shares of Insmed (INSM) via Merrill Lynch with an aggregate market value of $1,215,350 and an approximate sale date of 08/12/2025 on NASDAQ.

How large is the 10,000-share block relative to Insmed's outstanding shares?

The filing lists 211,374,786 shares outstanding, so 10,000 shares represent approximately 0.0047% of outstanding shares.

Who is the broker handling the proposed sale in the INSM Form 144?

The broker is listed as Merrill Lynch, 4705 S Apopka Vineland Rd Suite 203, Orlando, FL.

When were the securities proposed for sale originally acquired?

Two acquisition entries are shown: 6,702 shares acquired via stock option on 05/18/2018, and 6,066 shares acquired via stock option on 05/16/2019.

Does the filing state whether the seller possesses undisclosed material information?

The form includes the standard representation that the person for whose account the securities are to be sold does not know any material adverse information about the issuer that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001182633
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	INSMED Inc
SEC File Number	000-30739
Address of Issuer	700 US HIGHWAY 202/206 BRIDGEWATER NEW JERSEY 08807
Phone	908-977-9900
Name of Person for Whose Account the Securities are To Be Sold	SHAROKY MELVIN MD
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 4705 S Apopka Vineland Rd Suite 203 Orlando FL 32812	10000	1215350.00	211374786	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/16/2019	stock options	Melvin Sharoky			6066	05/16/2019	Stock Option
Common	05/18/2018	Stock Option	Melvin Sharoky			6702	05/18/2018	Stock Option

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/12/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Melvin Sharoky
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)